Navigation Links
Horphag's Prelox provides over-the-counter solution

For couples worldwide, erectile dysfunction (ED) is one of the leading contributors to a man's inability to perform. As millions of men in America each year look for a solution, many seek alternative treatments to prescription medications and surgery that may have dangerous side effects. A new published study reveals that Prelox, a patented and proprietary blend of Pycnogenol, (pic-noj-en-all), an antioxidant plant extract from the bark of the French maritime pine tree, combined with L-Arginine aspartate, an amino acid, is the natural answer to enhancing erectile quality.

The study, to be published in an upcoming edition of the International Journal of Impotence Research, shows improvement in men with ED after just one day. The study investigated the mechanism involved in relaxation of arteries as it is required for improved blood flow in erectile function. Prelox was found to cause a markedly increased nitric oxide production, the key mediator involved in expanding arteries for elevated blood flow during erections. By the end of the study, all men taking Prelox experienced almost a 100 percent increase of orgasmic function, sexual desire, intercourse satisfaction and overall satisfaction.

Prelox is a patented unique blend of two circulation-enhancing ingredients including Pycnogenol, which contains powerful bioflavonoids that originate from plants and help keep blood vessels dilated for optimal blood flow. L-Arginine, an amino acid found in many foods, is the other ingredient coupled with Pycnogenol that ultimately promotes blood flow.

Pycnogenol and L-Arginine work together to enhance nitric oxide, a crucial chemical for sexual arousal, said Steven Lamm MD, from New York University School of Medicine Prelox is the perfect solution for men who want the same outcome as other prescription nitric oxide enhancers, but with a natural approach.

The randomized placebo-controlled study was conducted at the Medical University of Sofia, Bulgaria. Fifty patients with moderate erectile problems were asked to take two Prelox or placebo tablets in the morning and evening. The erectile quality of men was monitored using the same methodology as applied in clinical trial with pharmaceutical drugs - in a diary consisting of a questionnaire. In addition, semen, spermatozoa and blood samples were collected to measure nitric oxide and testosterone. The study consisted of a four-week period, followed by a wash-out period, another four-week period, and a final washout.

At the end of the treatment period, patients treated with Prelox achieved high questionnaire scores, whereas the placebo group had no significant effects. The erectile function score of men (mean age 37 years) at trial start was in average 14 out of a maximum 30. After one month on Prelox, the erectile function score increased to 27, which resembles almost completely healthy values such as those found in twenty year old men. Parallel to the increase of erectile function, the mean number of intercourse more than doubled during treatment for those who took Prelox. Treatment with Prelox produced a steep increase of nitric oxide activity in most patients and no changes were indicated for the placebo group.

This European study confirms my experience in a clinical trial with Prelox I carried out two years ago said Lamm. "This is the third clinical study showing that men can achieve greater erectile quality with Prelox, move past their performance anxiety and get more satisfaction from their sex lives."

Blood analysis revealed an increased testosterone level during supplementation with Prelox. This is not a direct result of the supplement but is typical for men with increased sexual activity. The men in this trial reported a dramatic increased frequency of morning erections. Moreover, their partners noted a higher interest for sex as well as better performance.

Past research on Prelox scientifically demonstrated its effectiveness in increasing and enhancing sexual performance in three clinical studies in the United States and Europe. In these studies, almost 85 percent of Prelox users said it improved erectile function and more than 70 percent of Prelox users said it was easier to initiate and sustain an erection. In a study at the New York University School of Medicine, more than 80 percent of male subjects rated Prelox as effective in improving their ability to engage in sexual activity.

Furthering evidence of its effectiveness, Prelox has been awarded a U.S. patent (U.S. 6,565,851 B2) for the relief of the symptoms of erectile dysfunction. NHS and Horphag Research have granted exclusive product licenses to several companies world-wide. Horphag Research just announced a new partnership with Xion Corporation. Xion will launch Prelox to practitioners in North America.

Prelox is safe and easy to use "two tablets, twice a day for the first two weeks; then one to two tablets, twice a day to maintain and sustain enhanced pleasure and performance. Prelox is exclusively available at Purity Products , Herbalife, GVI and Xion. For more information visit


Contact: Melanie Nimrodi
MWW Group  

Related medicine news :

1. Study provides hope that some transplant patients could live free of antirejection drugs
2. Study provides hope that some transplant patients could live free of anti-rejection drugs
3. USAID Provides Additional Wildfire Assistance to Greece
4. Proven Nutrition Provides Energy and Hope to Cancer Fighters
5. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
6. New knock-out gene model provides molecular clues to breast cancer
7. PreMD Provides Update on 510(k) Application for PREVU(x) POC
8. SIV infection of natural hosts provides new insights into HIV disease complexity
9. Microarray provides 3 genomic guides to breast cancer treatment decisions
10. Access Innovations Provides Support Services for Agis Network
11. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
Post Your Comments:
Related Image:
Horphag's Prelox provides over-the-counter solution
(Date:11/30/2015)... ... November 30, 2015 , ... Using a combination of two blood ... children and adults, according to a new study by researchers at the School of ... Children and Adults: Using Combinations of Blood Glucose Tests ,” published in Frontiers in ...
(Date:11/30/2015)... ... November 30, 2015 , ... Newly reviewed and approved “NJ Top ... from Tufts School of Dental Medicine in 1935. His father graduated from NYU ... being in dentistry as well as their commitment and passion to the Practice of ...
(Date:11/30/2015)... York, NY (PRWEB) , ... November 30, 2015 , ... ... York Times,” will be released on December 1, 2015, to coincide with World AIDS ... about the groundbreaking journalist who covered the AIDS epidemic as he was dying of ...
(Date:11/30/2015)... ... November 30, 2015 , ... The American Society for ... honor of World AIDS Day 2015. On Nov. 30, ASCP shared its “Give a ... about World AIDS Day and the importance of getting tested for HIV. , ASCP ...
(Date:11/30/2015)... ... 30, 2015 , ... California-based i2i Systems, a pioneer defining ... Michigan-based Family Health Center (FHC) has selected i2iTracks as their population health management ... the largest Affordable Care Act grant for Federally Qualified Health Centers in the ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , Nov. 30, 2015  Kevin Smith ... Sensium Healthcare, a global pioneer in wireless monitoring ... Boston, MA , Mr. Smith will ... Sensium,s global commercial strategy.  He will also directly ... to build clinical evidence for SensiumVitals, the first ...
(Date:11/30/2015)... , Nov. 30, 2015  The fee-for-service ... in U.S. medical imaging is on its ... accountable care payer-provider contracts are set to ... their wake, alter provider-vendor relationships. The shift ... push forward new purchasing frameworks in the ...
(Date:11/30/2015)... WOODCLIFF LAKE, N.J. and SAN ... Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) ... (FDA) has accepted for filing the New Drug Application ... approved, the extended release formulation will offer patients a ... ® ) is currently approved as ...
Breaking Medicine Technology: